Eric Konofal
3 presentations
-
W53. A NOVEL DISEASE-MODIFYING STRATEGY FOR NARCOLEPSY TYPE 1 – PRECLINICAL RATIONALE AND DEVELOPMENT ROADMAP FOR THE DOXA PLATFORM
-
T12. MAZINDOL IR/SR: A 50-YEAR LEGACY REPOSITIONED AS A FIRST-IN-CLASS OREXIN–MONOAMINE MODULATOR FOR ADHD AND AROUSAL-RELATED DISORDERS
-
T13. COMPREHENSIVE MULTITARGET STRATEGY FOR TYPE 1 DIABETES AND ASSOCIATED NEUROLOGICAL/SLEEP DISORDERS (DANS): INTEGRATING STEM-CELL-DERIVED ISLET REPLACEMENT, IMMUNE MODULATION, AND NEURO-CIRCADIAN THERAPEUTICS